Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Lung Cancer

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 134 articles:
HTML format



Single Articles


    October 2021
  1. MATSUBARA T, Hirai F, Yamaguchi M, Hamatake M, et al
    Immunonutritional Indices in Non-small-cell Lung Cancer Patients Receiving Adjuvant Platinum-based Chemotherapy.
    Anticancer Res. 2021;41:5157-5163.
    PubMed     Abstract available


  2. MITSUYA S, Tsuruoka K, Kanaoka K, Funamoto T, et al
    Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis.
    Anticancer Res. 2021;41:5137-5145.
    PubMed     Abstract available


  3. HAMADA K, Yoshimura K, Hirasawa Y, Hosonuma M, et al
    Antibiotic Usage Reduced Overall Survival by over 70% in Non-small Cell Lung Cancer Patients on Anti-PD-1 Immunotherapy.
    Anticancer Res. 2021;41:4985-4993.
    PubMed     Abstract available


  4. SON KH, Kim MY, Shin JY, Kim JO, et al
    Synergistic Antitumor Effect of Taxanes and CDK4/6 Inhibitor in Lung Cancer Cells and Mice Harboring KRAS Mutations.
    Anticancer Res. 2021;41:4807-4820.
    PubMed     Abstract available


  5. ARAKI K, Yamamuro N, Tomonobu N, Kumon H, et al
    REIC/Dkk-3 Gene Therapy Induces Immunogenic Cell Death in a Mouse Model of Malignant Mesothelioma.
    Anticancer Res. 2021;41:4837-4855.
    PubMed     Abstract available


  6. VODICKA J, Skala M, Sebek J, Treska V, et al
    The Role of Serum Tumor Markers in Follow-up After Surgical Treatment of Malignant Lung Tumors.
    Anticancer Res. 2021;41:5117-5122.
    PubMed     Abstract available


  7. JANSSEN S, Overhoff D, Froelich MF, Schoenberg SO, et al
    Detectability of Lung Nodules in Ultra-low Dose CT.
    Anticancer Res. 2021;41:5053-5058.
    PubMed     Abstract available


  8. KINOSHITA H, Shimozato O, Ishii T, Kamoda H, et al
    The Thioredoxin Reductase Inhibitor Auranofin Suppresses Pulmonary Metastasis of Osteosarcoma, But Not Local Progression.
    Anticancer Res. 2021;41:4947-4955.
    PubMed     Abstract available


    September 2021
  9. SURAPANENI SK, Nottingham E, Mondal A, Patel N, et al
    Telmisartan Facilitates the Anticancer Effects of CARP-1 Functional Mimetic and Sorafenib in Rociletinib Resistant Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:4215-4228.
    PubMed     Abstract available


  10. KIM SW, DO SI, Na K
    External Validation of ALK and ROS1 Fusions Detected Using an Oncomine Comprehensive Assay.
    Anticancer Res. 2021;41:4609-4617.
    PubMed     Abstract available


  11. YOSHIDA D, Kusunoki T, Takayama Y, Kusano Y, et al
    Comparison of Dose Distribution Between VMAT-SBRT and Scanning Carbon-ion Radiotherapy for Early-stage NSCLC.
    Anticancer Res. 2021;41:4571-4575.
    PubMed     Abstract available


  12. MIRKA H, Ferda J, Krakorova G, Vodicka J, et al
    The Use of CT Pattern in Differentiating Non-invasive, Minimally Invasive and Invasive Variants of Lung Adenocarcinoma.
    Anticancer Res. 2021;41:4479-4482.
    PubMed     Abstract available


  13. SUZUKI S, Yamamoto M, Sanomachi T, Togashi K, et al
    Lurasidone Sensitizes Cancer Cells to Osimertinib by Inducing Autophagy and Reduction of Survivin.
    Anticancer Res. 2021;41:4321-4331.
    PubMed     Abstract available


    August 2021
  14. GIATROMANOLAKI A, Anestopoulos I, Panayiotidis MI, Mitrakas A, et al
    Prognostic Relevance of the Relative Presence of CD4, CD8 and CD20 Expressing Tumor Infiltrating Lymphocytes in Operable Non-small Cell Lung Cancer Patients.
    Anticancer Res. 2021;41:3989-3995.
    PubMed     Abstract available


  15. LAFAUY P, Silapech A, Aksorn N, Sritularak B, et al
    Millettocalyxin B Inhibits Migratory Behavior of Lung Cancer Cells via Integrin alpha5 Suppression.
    Anticancer Res. 2021;41:3843-3849.
    PubMed     Abstract available


  16. OTSUKA T, Ueda K, Furukawa T, Koriyama C, et al
    Significance of Mitochondrial DNA Haplogroup on Epidermal Growth Factor Receptor Mutation in Japanese Patients With Lung Adenocarcinoma.
    Anticancer Res. 2021;41:3997-4004.
    PubMed     Abstract available


  17. YAMANAKA M, Hayashi M, Yamada S, Sonohara F, et al
    A Possible Definition of Oligometastasis in Pancreatic Cancer and Associated Survival Outcomes.
    Anticancer Res. 2021;41:3933-3940.
    PubMed     Abstract available


    July 2021
  18. SHIONOYA Y, Hirohashi Y, Takahashi H, Hashimoto M, et al
    Possible Pseudo-progression of Non-small Cell Lung Carcinoma in a Patient With Clinical Hyper-progression Associated With Trousseau Syndrome Who Was Treated With Pembrolizumab: A Case Report.
    Anticancer Res. 2021;41:3699-3706.
    PubMed     Abstract available


  19. ZAITSU J, Yamashita Y, Ishikawa A, Saito A, et al
    Systemic Inflammatory Score Predicts Response and Prognosis in Patients With Lung Cancer Treated With Immunotherapy.
    Anticancer Res. 2021;41:3673-3682.
    PubMed     Abstract available


  20. JANG SK, Hong SE, Lee DH, Kim JY, et al
    Inhibition of AKT Enhances the Sensitivity of NSCLC Cells to Metformin.
    Anticancer Res. 2021;41:3481-3487.
    PubMed     Abstract available


    June 2021
  21. LEE GD, Chung B, Song JS, Jang SJ, et al
    The Prognostic Value of Programmed Death-ligand 1 (PD-L1) in Patients who Received Neoadjuvant Chemoradiation Therapy Followed by Surgery for Locally Advanced Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:3193-3204.
    PubMed     Abstract available


  22. MOHIUDDIN MD, Kasahara K
    Pemetrexed Disodium Heptahydrate Induces Apoptosis and Cell-cycle Arrest in Non-small-cell Lung Cancer Carrying an EGFR Exon 19 Deletion.
    Anticancer Res. 2021;41:2963-2977.
    PubMed     Abstract available


  23. PUTRI HE, Sritularak B, Chanvorachote P
    DS-1 Inhibits Migration and Invasion of Non-small-cell Lung Cancer Cells Through Suppression of Epithelial to Mesenchymal Transition and Integrin beta1/FAK Signaling.
    Anticancer Res. 2021;41:2913-2923.
    PubMed     Abstract available


  24. KIM SY, Jeong EH, Lee TG, Kim HR, et al
    The Combination of Trametinib, a MEK Inhibitor, and Temsirolimus, an mTOR Inhibitor, Radiosensitizes Lung Cancer Cells.
    Anticancer Res. 2021;41:2885-2894.
    PubMed     Abstract available


  25. LIU YC, Hsu FT, Chung JG, Weng MC, et al
    Lenvatinib Induces AKT/NF-kappaB Inactivation, Apoptosis Signal Transduction and Growth Inhibition of Non-small Cell Lung Cancer In Vivo.
    Anticancer Res. 2021;41:2867-2874.
    PubMed     Abstract available


    May 2021
  26. MASUDA T, Wakabayashi YU, Nakashima T, Nishimura Y, et al
    Prognostic Significance of EGFR Gene Mutation in Patients With EGFR Mutated Non-small Cell Lung Cancer Who Received Best Supportive Care Alone.
    Anticancer Res. 2021;41:2661-2667.
    PubMed     Abstract available


  27. OKIMOTO T, Tsubata Y, Tanino R, Nakao M, et al
    ERCC1 Is a Predictive Biomarker for Non-small Cell Lung Cancer But Is Antibody-dependent.
    Anticancer Res. 2021;41:2653-2660.
    PubMed     Abstract available


  28. SUGIURA H, Miki Y, Iwabuchi E, Saito R, et al
    Estrogen Receptor beta Is Involved in Acquired Resistance to EGFR-tyrosine Kinase Inhibitors in Lung Cancer.
    Anticancer Res. 2021;41:2371-2381.
    PubMed     Abstract available


  29. KREJCI D, Opalka P, Krejci J, Zemanova M, et al
    Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment.
    Anticancer Res. 2021;41:2597-2603.
    PubMed     Abstract available


  30. AOKI K, Nagatani Y, Noma K, Tsugawa T, et al
    Effective Control of Brain Metastases Irrespective of Distance from Isocenter in Single-isocenter Multitarget Stereotactic Radiosurgery.
    Anticancer Res. 2021;41:2575-2581.
    PubMed     Abstract available


  31. HISAKANE K, Seike M, Sugano T, Matsuda K, et al
    PD-L1 Expression Status Predicting Survival in Pulmonary Pleomorphic Carcinoma.
    Anticancer Res. 2021;41:2501-2509.
    PubMed     Abstract available


  32. GUSHO CA, Blank AT
    What Is the Clinical Impact of Sending Tissue for Histopathology During Surgery for Known, Diffuse Metastatic Disease to Bone?
    Anticancer Res. 2021;41:2473-2476.
    PubMed     Abstract available


  33. SHIROSHITA A, Kurosaki M, Takeshita M, Kataoka Y, et al
    Medical Thoracoscopy, Computed Tomography-guided Biopsy, and Ultrasound-guided Biopsy for Malignant Pleural Mesothelioma: A Systematic Review.
    Anticancer Res. 2021;41:2217-2225.
    PubMed     Abstract available


    April 2021
  34. TSUKIOKA T, Izumi N, Komatsu H, Inoue H, et al
    Tumor Size and N2 Lymph Node Metastasis Are Significant Risk Factors for Early Recurrence in Completely Resected Centrally Located Primary Lung Cancer Patients.
    Anticancer Res. 2021;41:2165-2169.
    PubMed     Abstract available


  35. TOZUKA T, Yanagitani N, Yoshida H, Manabe R, et al
    Impact of Renin-angiotensin System Inhibitors on the Efficacy of Anti-PD-1/PD-L1 Antibodies in NSCLC Patients.
    Anticancer Res. 2021;41:2093-2100.
    PubMed     Abstract available


  36. SVATON M, Bratova M, Fischer O, Krejci J, et al
    Real-life Effectiveness of Afatinib Versus Gefitinib in Patients With Non-small-cell Lung Cancer: A Czech Multicentre Study.
    Anticancer Res. 2021;41:2059-2065.
    PubMed     Abstract available


  37. MON MM, Srisomsap C, Chokchaichamnankit D, Watcharatanyatip K, et al
    Serum Proteomic Profiling Reveals Differentially Expressed IGHG3 and A1AG1 as Potential Predictors of Chemotherapeutic Response in Advanced Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:1871-1882.
    PubMed     Abstract available


  38. SVATON M, Blazek J, Krakorova G, Pesek M, et al
    Prognostic Role for CYFRA 21-1 in Patients With Advanced-stage NSCLC Treated With Bevacizumab Plus Chemotherapy.
    Anticancer Res. 2021;41:2053-2058.
    PubMed     Abstract available


  39. SHIBA S, Shibuya K, Okamoto M, Okano N, et al
    Carbon-ion Radiotherapy for Oligometastatic Colorectal Cancer in the Liver or Lung.
    Anticancer Res. 2021;41:1997-2005.
    PubMed     Abstract available


    March 2021
  40. IWASHITA K, Mizuno T, Kumazawa S, Imaizumi K, et al
    Drug-induced Interstitial Lung Disease Has the Same Degree of Risk for Mortality as Old Age in Patients With Lung Cancer.
    Anticancer Res. 2021;41:1707-1711.
    PubMed     Abstract available


  41. ASANO Y, Yamamoto N, Hayashi K, Takeuchi A, et al
    Complete Response of Bone Metastasis in Non-small Cell Lung Cancer With Pembrolizumab: Two Case Reports.
    Anticancer Res. 2021;41:1693-1699.
    PubMed     Abstract available


  42. HIRASHIMA T, Noda Y, Suzuki H, Nasu S, et al
    Extracellular Water-to-total Body Water Ratio as an Objective Biomarker for Frailty in Lung Cancer Patients.
    Anticancer Res. 2021;41:1655-1662.
    PubMed     Abstract available


  43. SATO Y, Iihara H, Kinomura M, Hirose C, et al
    Primary Prophylaxis of Febrile Neutropenia With Pegfilgrastim in Small-cell Lung Cancer Patients Receiving Amrubicin as Second-line Therapy.
    Anticancer Res. 2021;41:1615-1620.
    PubMed     Abstract available


  44. DIMAKAKOS E, Livanios K, Vathiotis I, Gomatou G, et al
    Risk Factors for Venous Thromboembolism in Patients With Small Cell Lung Cancer.
    Anticancer Res. 2021;41:1523-1528.
    PubMed     Abstract available


  45. ITO N, Masuda T, Nakashima T, Nakao S, et al
    Autoantibody Positivity Is a Risk Factor for Chemotherapy-induced Exacerbation of Interstitial Pneumonia in Lung Cancer.
    Anticancer Res. 2021;41:1497-1506.
    PubMed     Abstract available


  46. CHEN WT, Chen CH, Su HT, Yueh PF, et al
    Amentoflavone Induces Cell-cycle Arrest, Apoptosis, and Invasion Inhibition in Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2021;41:1357-1364.
    PubMed     Abstract available


  47. LEE HK, Noh MH, Hong SW, Kim SM, et al
    Erlotinib Activates Different Cell Death Pathways in EGFR-mutant Lung Cancer Cells Grown in 3D Versus 2D Culture Systems.
    Anticancer Res. 2021;41:1261-1269.
    PubMed     Abstract available


  48. GRIESING S, Liao BC, Yang JC
    CD73 Is Regulated by the EGFR-ERK Signaling Pathway in Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:1231-1242.
    PubMed     Abstract available


  49. FUKUDA N, Toda K, Ohmoto A, Wang X, et al
    Baseline Tumour Size as a Prognostic Factor for Radioiodine-refractory Differentiated Thyroid Cancer Treated With Lenvatinib.
    Anticancer Res. 2021;41:1683-1691.
    PubMed     Abstract available


  50. KINOSHITA F, Yamashita T, Oku Y, Kosai K, et al
    Prognostic Impact of Albumin-bilirubin (ALBI) Grade on Non-small Lung Cell Carcinoma: A Propensity-score Matched Analysis.
    Anticancer Res. 2021;41:1621-1628.
    PubMed     Abstract available


  51. NIEDER C, Mannsaker B, Yobuta R
    Independent Validation of a Comprehensive Machine Learning Approach Predicting Survival After Radiotherapy for Bone Metastases.
    Anticancer Res. 2021;41:1471-1474.
    PubMed     Abstract available


    February 2021
  52. AKAMATSU H, Ozawa Y, Oyanagi J, Fujimoto D, et al
    Phase Ib Study of Osimertinib Plus Ramucirumab in Japanese Lung Cancer Patients With EGFR Mutation.
    Anticancer Res. 2021;41:911-917.
    PubMed     Abstract available


  53. CLEVERS MR, Kastelijn EA, Peters BJM, Kelder H, et al
    Evaluation of Serum Biomarker CEA and Ca-125 as Immunotherapy Response Predictors in Metastatic Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:869-876.
    PubMed     Abstract available


  54. WEE CW, Kim JH, Kim HJ, Kang HC, et al
    Newly Synthesized DNA Methyltransferase Inhibitors as Radiosensitizers for Human Lung Cancer and Glioblastoma Cells.
    Anticancer Res. 2021;41:757-764.
    PubMed     Abstract available


  55. YAMAMOTO J, Aoki Y, Han Q, Sugisawa N, et al
    Reversion from Methionine Addiction to Methionine Independence Results in Loss of Tumorigenic Potential of Highly-malignant Lung-cancer Cells.
    Anticancer Res. 2021;41:641-643.
    PubMed     Abstract available


  56. YAMASHITA N, Oyama T, So T, Miyata T, et al
    Association Between CD133 Expression and Prognosis in Human Lung Adenocarcinoma.
    Anticancer Res. 2021;41:905-910.
    PubMed     Abstract available


  57. OSHIRO H, Tome Y, Miyake K, Higuchi T, et al
    A Novel Orthotopic Mouse Model of Lung Metastasis Using Fluorescent Patient-derived Osteosarcoma Cells.
    Anticancer Res. 2021;41:635-640.
    PubMed     Abstract available


    January 2021
  58. NIEDER C, Imingen KS, Mannsaker B, Yobuta R, et al
    Palliative Thoracic Radiotherapy for Non-small Cell Lung Cancer: Is There any Impact of Target Volume Size on Survival?
    Anticancer Res. 2021;41:355-358.
    PubMed     Abstract available


  59. LIU YC, Huang BH, Chung JG, Liu WL, et al
    Lenvatinib Inhibits AKT/NF-kappaB Signaling and Induces Apoptosis Through Extrinsic/Intrinsic Pathways in Non-small Cell Lung Cancer.
    Anticancer Res. 2021;41:123-130.
    PubMed     Abstract available


  60. KAWABATA S, Connis N, Gills JJ, Hann CL, et al
    Nelfinavir Inhibits the Growth of Small-cell Lung Cancer Cells and Patient-derived Xenograft Tumors.
    Anticancer Res. 2021;41:91-99.
    PubMed     Abstract available


    December 2020
  61. ASHI N, Kataoka Y, Takemura T, Shirakawa C, et al
    Factors Influencing Social Isolation and Loneliness Among Lung Cancer Patients: A Cross-sectional Study.
    Anticancer Res. 2020;40:7141-7145.
    PubMed     Abstract available


  62. LIU B, Shiraga S, Mortenson MM, Lai J, et al
    Small Cell Lung Carcinoma and Synchronous Rectal Adenocarcinoma and Jejunal Gastrointestinal Stromal Tumor Present in a Patient With History of Laryngeal Squamous Cell Carcinoma.
    Anticancer Res. 2020;40:7053-7056.
    PubMed     Abstract available


  63. VODICKA J, Fichtl J, Sebek J, ProchAzkovA K, et al
    Outcomes and Prognostic Factors Following Surgical Treatment of Pulmonary Metastases from Colorectal Carcinoma.
    Anticancer Res. 2020;40:7045-7051.
    PubMed     Abstract available


  64. HIRASHIMA T, Kanai T, Suzuki H, Yoshida H, et al
    Significance of Pre-treatment Interferon-gamma Release in Patients With Non-small-cell Lung Cancer Receiving Immune Checkpoint Inhibitors.
    Anticancer Res. 2020;40:6971-6978.
    PubMed     Abstract available


  65. MORIMOTO M, Nishino K, Wada K, Imamura F, et al
    Elective Nodal Irradiation for Non-small Cell Lung Cancer Complicated With Chronic Obstructive Pulmonary Disease Affects Immunotherapy Alphafter Definitive Chemoradiotherapy.
    Anticancer Res. 2020;40:6957-6970.
    PubMed     Abstract available


  66. YOON JH, Cho SG
    ADGRF4 Regulates Non-small Cell Lung Cancer Cell Invasiveness.
    Anticancer Res. 2020;40:6835-6844.
    PubMed     Abstract available


  67. WATANABE T, Sawabata N, Kawaguchi T, Yoshikawa D, et al
    Clustered Circulating Tumor Cells in Lung Adenocarcinoma: Implications of Test Results of Continuous Variables.
    Anticancer Res. 2020;40:7089-7094.
    PubMed     Abstract available


    November 2020
  68. NAGASHIMA T, Oshima T, Hiroshima Y, Yokose T, et al
    Clinical Significance of Tumour CD44v and MIST1 Expression in Patients With Non-small-cell Lung Cancer.
    Anticancer Res. 2020;40:6407-6416.
    PubMed     Abstract available


  69. SJOGREN K, Jacobsen KA, GrOnberg BH, Halvorsen TO, et al
    Timing of Severe Toxicity from Chemotherapy in Patients With Lung Cancer.
    Anticancer Res. 2020;40:6399-6406.
    PubMed     Abstract available


  70. LEE SY, Slagle-Webb B, Sharma AK, Connor JR, et al
    Characterization of a Novel Barbituric Acid and Two Thiobarbituric Acid Compounds for Lung Cancer Treatment.
    Anticancer Res. 2020;40:6039-6049.
    PubMed     Abstract available


  71. HORIGUCHI H, Tsujimoto H, Shinomiya N, Matsumoto Y, et al
    A Potential Role of Adhesion Molecules on Lung Metastasis Enhanced by Local Inflammation.
    Anticancer Res. 2020;40:6171-6178.
    PubMed     Abstract available


    October 2020
  72. CHEN HJ, Tu CY, Hsia TC, Fang HY, et al
    Prognostic Significance of Oligometastatic Disease Classification by the ESTRO/EORTC of Cancer for Patients With Lung Cancer Treated With Definitive Radical Radiotherapy.
    Anticancer Res. 2020;40:5895-5899.
    PubMed     Abstract available


  73. BASSO SMM, Del Conte A, Zuccon U, Sulfaro SC, et al
    Diagnostic Accuracy of Pleural Fluid Cytology, Carcinoembryonic Antigen and C-Reactive Protein Together in Patients With Pulmonary Metastases and Malignant Pleural Effusion.
    Anticancer Res. 2020;40:5877-5881.
    PubMed     Abstract available


  74. YAMADA Y, Tamura T, Yamamoto Y, Ichimura H, et al
    Treatment of Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in Clinical Practice.
    Anticancer Res. 2020;40:5757-5764.
    PubMed     Abstract available


  75. BALBINOTTI H, Cadore NA, Dutra CS, DA Silva ED, et al
    Protein Profiling of Extracellular Vesicles Associated With Cisplatin Resistance in Lung Cancer.
    Anticancer Res. 2020;40:5509-5516.
    PubMed     Abstract available


  76. HAAG A, Jayakrishnan T, Shah D, Sandhu A, et al
    First Reported Case of Localized Extra-pulmonary Small Cell Carcinoma (EPSC) of the Esophagus Treated With Triple Therapy.
    Anticancer Res. 2020;40:5919-5923.
    PubMed     Abstract available


  77. SIMONI N, Micera R, Rossi G, Giri MG, et al
    Predictors of Local Control for Stereotactic Ablative Radiotherapy (SAbR) in Pulmonary Oligometastases from Gastrointestinal Malignancies.
    Anticancer Res. 2020;40:5901-5907.
    PubMed     Abstract available


  78. MANOHARAN A, Lugo-Baruqui A, Ciancio G
    Radical Nephrectomy and Pulmonary Lobectomy for Renal Cell Carcinoma With Tumor Thrombus Extension into the Inferior Vena Cava and Pulmonary Arteries.
    Anticancer Res. 2020;40:5837-5844.
    PubMed     Abstract available


  79. KITAHARA H, Okamoto T, Shimamatsu S, Kohno M, et al
    LINE-1 Hypomethylation Is Associated With Malignant Traits and Cell Proliferation in Lung Adenocarcinoma.
    Anticancer Res. 2020;40:5659-5666.
    PubMed     Abstract available


  80. SONODA T, Yanagitani N, Suga K, Yoshizawa T, et al
    A Novel System to Detect Circulating Tumor Cells Using Two Different Size-selective Microfilters.
    Anticancer Res. 2020;40:5577-5582.
    PubMed     Abstract available


  81. GERGEN AK, Kohtz PD, Halpern AL, Li A, et al
    Activation of Toll-Like Receptor 2 Promotes Proliferation of Human Lung Adenocarcinoma Cells.
    Anticancer Res. 2020;40:5361-5369.
    PubMed     Abstract available


    September 2020
  82. KOBAYASHI K, Kaira K, Kagamu H
    Recovery of the Sensitivity to Anti-PD-1 Antibody by Celecoxib in Lung Cancer.
    Anticancer Res. 2020;40:5309-5311.
    PubMed     Abstract available


  83. NONPANYA N, Prakhongcheep O, Petsri K, Jitjaicham C, et al
    Ephemeranthol A Suppresses Epithelial to Mesenchymal Transition and FAK-Akt Signaling in Lung Cancer Cells.
    Anticancer Res. 2020;40:4989-4999.
    PubMed     Abstract available


  84. CHEN HL, Gong JY, Lin SC, Li S, et al
    Effects of Sclareol Against Small Cell Lung Carcinoma and the Related Mechanism: In Vitro and In Vivo Studies.
    Anticancer Res. 2020;40:4947-4960.
    PubMed     Abstract available


  85. FLESCHUTZ K, Walter L, Leistner R, Heinzerling L, et al
    ALK Inhibitors Do Not Increase Sensitivity to Radiation in EML4-ALK Non-small Cell Lung Cancer.
    Anticancer Res. 2020;40:4937-4946.
    PubMed     Abstract available


  86. HALLEY A, Leonetti A, Gregori A, Tiseo M, et al
    The Role of the Microbiome in Cancer and Therapy Efficacy: Focus on Lung Cancer.
    Anticancer Res. 2020;40:4807-4818.
    PubMed     Abstract available


  87. SUGISAWA N, Hamada K, Han Q, Yamamoto J, et al
    Adjuvant Oral Recombinant Methioninase Inhibits Lung Metastasis in a Surgical Breast-Cancer Orthotopic Syngeneic Model.
    Anticancer Res. 2020;40:4869-4874.
    PubMed     Abstract available


    August 2020
  88. NAKAO T, Okuda T, Yoshioka H, Fujita M, et al
    Clinical Outcomes of Surgical Resection for Brain Metastases from Non-small Cell Lung Cancer.
    Anticancer Res. 2020;40:4801-4804.
    PubMed     Abstract available


  89. TAKAHASHI Y, Soh J, Shien K, Yamamoto H, et al
    Fibrosis or Necrosis in Resected Lymph Node Indicate Metastasis Before Chemoradiotherapy in Lung Cancer Patients.
    Anticancer Res. 2020;40:4419-4423.
    PubMed     Abstract available


  90. TAKAHASHI S, Go T, Anada M, Kinoshita T, et al
    Correlation of Pathological Complete Response With Tumor Volume Reduction During Neoadjuvant Chemoradiotherapy in Lung Cancer.
    Anticancer Res. 2020;40:4327-4330.
    PubMed     Abstract available


  91. TAKEUCHI A, Oguri T, Fukuda S, Sone K, et al
    Variants of SLC22A16 Predict the Efficacy of Platinum Combination Chemotherapy in Advanced Non-small-cell Lung Cancer.
    Anticancer Res. 2020;40:4245-4251.
    PubMed     Abstract available


  92. TAMIYA A, Tamiya M, Go H, Inoue T, et al
    A Multivariable Regression Model-based Nomogram for Estimating the Overall Survival of Patients Previously Treated With Nivolumab for Advanced Non-small-cell Lung Cancer.
    Anticancer Res. 2020;40:4229-4236.
    PubMed     Abstract available


  93. CZAJKA M, Zajkowska A, Gawlak M, Bujalska-Zadrozny M, et al
    Mosaic Recombinant Adeno-associated Virus Vector rAAV/DJ/CAG for Targeted Gene Delivery to Melanoma Cells Metastasized to the Lung.
    Anticancer Res. 2020;40:4425-4444.
    PubMed     Abstract available


  94. CAO C, Kong MX, Kapali M, Moezardalan K, et al
    EGFR Mutated Lung Adenocarcinoma Metastasis to the Pancreas Mimicking Primary Pancreatic Ductal Carcinoma.
    Anticancer Res. 2020;40:4401-4404.
    PubMed     Abstract available


    July 2020
  95. HOHNECK A, Shchetynska-Marinova T, Ruemenapf G, Pancheva M, et al
    Coprevalence and Incidence of Lung Cancer in Patients Screened for Abdominal Aortic Aneurysm.
    Anticancer Res. 2020;40:4137-4145.
    PubMed     Abstract available


  96. UEDA Y, Suzuki O, Ohira S, Yagi M, et al
    The Promising Treatment Schedule of Concurrent Chemoradiotherapy for Stage III Non-small Cell Lung Cancer: Alternative for Conventional Fractionation Using Mathematical Analysis.
    Anticancer Res. 2020;40:4095-4104.
    PubMed     Abstract available


  97. TOMITA M, Maeda R, Ayabe T, Nakamura K, et al
    Prognostic Impact of a Novel Tumor Marker and Inflammation Index for Patients With Non-small-cell Lung Cancer.
    Anticancer Res. 2020;40:4023-4027.
    PubMed     Abstract available


  98. NODA Y, Suzuki H, Kanai T, Samejima Y, et al
    The Association Between Extracellular Water-to-Total Body Water Ratio and Therapeutic Durability for Advanced Lung Cancer.
    Anticancer Res. 2020;40:3931-3937.
    PubMed     Abstract available


  99. KUBO S, Kobayashi N, Somekawa K, Hirata M, et al
    Identification of Biomarkers for Non-small-cell Lung Cancer Patients Treated With an Immune Checkpoint Inhibitor.
    Anticancer Res. 2020;40:3889-3896.
    PubMed     Abstract available


  100. ORYWAL K, Jelski W, KozLowski MD, Mroczko B, et al
    Activity of Alcohol Dehydrogenase and Aldehyde Dehydrogenase in Lung Cancer Cells.
    Anticancer Res. 2020;40:3857-3863.
    PubMed     Abstract available


    June 2020
  101. ABE T, Kobayashi N, Aoshika T, Ryuno Y, et al
    Pattern of Local Failure and its Risk Factors of Locally Advanced Non-small Cell Lung Cancer Treated With Concurrent Chemo-radiotherapy.
    Anticancer Res. 2020;40:3513-3517.
    PubMed     Abstract available


  102. BAXA J, Ludvik J, Sedlmair M, Flohr T, et al
    Correlation of Iodine Quantification and FDG Uptake in Early Therapy Response Assessment of Non-small Cell Lung Cancer: Possible Benefit of Dual-energy CT Scan as an Integral Part of PET/CT Examination.
    Anticancer Res. 2020;40:3459-3468.
    PubMed     Abstract available


  103. MOON SM, Kim JH, Kim SK, Kim S, et al
    Clinical Utility of Combined Circulating Tumor Cell and Circulating Tumor DNA Assays for Diagnosis of Primary Lung Cancer.
    Anticancer Res. 2020;40:3435-3444.
    PubMed     Abstract available


  104. TAKAHASHI K, Menju T, Nishikawa S, Miyata R, et al
    Tranilast Inhibits TGF-beta1-induced Epithelial-mesenchymal Transition and Invasion/Metastasis via the Suppression of Smad4 in Human Lung Cancer Cell Lines.
    Anticancer Res. 2020;40:3287-3296.
    PubMed     Abstract available


  105. KIM B, Kim SW, Lim JY, Park SJ, et al
    NCAPH Is Required for Proliferation, Migration and Invasion of Non-small-cell Lung Cancer Cells.
    Anticancer Res. 2020;40:3239-3246.
    PubMed     Abstract available


  106. SP N, Kang DY, Kim DH, Yoo JS, et al
    Tannic Acid Inhibits Non-small Cell Lung Cancer (NSCLC) Stemness by Inducing G0/G1 Cell Cycle Arrest and Intrinsic Apoptosis.
    Anticancer Res. 2020;40:3209-3220.
    PubMed     Abstract available


  107. SCHMIDT-WOLF R, Zissel G
    Interaction Between CCL18 and GPR30 Differs from the Interaction Between Estradiol and GPR30.
    Anticancer Res. 2020;40:3097-3108.
    PubMed     Abstract available


  108. PALUMBO B, Capozzi R, Bianconi F, Fravolini ML, et al
    Classification Model to Estimate MIB-1 (Ki 67) Proliferation Index in NSCLC Patients Evaluated With (18)F-FDG-PET/CT.
    Anticancer Res. 2020;40:3355-3360.
    PubMed     Abstract available


    May 2020
  109. YOSHIDA H, Kim YH, Sakamori Y, Nagai H, et al
    A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer.
    Anticancer Res. 2020;40:2981-2987.
    PubMed     Abstract available


  110. RADES D, Nguyen T, Khoa MT, Janssen S, et al
    Evaluation of Five Survival Scores in a Cohort of Elderly Patients With Cerebral Metastasis from Non-small Cell Lung Cancer.
    Anticancer Res. 2020;40:2847-2851.
    PubMed     Abstract available


  111. KANAI T, Suzuki H, Yoshida H, Matsushita A, et al
    Significance of Quantitative Interferon-gamma Levels in Non-small-cell Lung Cancer Patients' Response to Immune Checkpoint Inhibitors.
    Anticancer Res. 2020;40:2787-2793.
    PubMed     Abstract available


  112. MIYAUCHI S, Shien K, Takeda T, Araki K, et al
    Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic BRAF Mutation.
    Anticancer Res. 2020;40:2667-2673.
    PubMed     Abstract available


  113. SRIRATANASAK N, Nonpanya N, Wattanathana W, Chanvorachote P, et al
    Benzoxazine Dimer Analogue Targets Integrin beta3 in Lung Cancer Cells and Suppresses Anoikis Resistance and Migration.
    Anticancer Res. 2020;40:2583-2589.
    PubMed     Abstract available


  114. LEE TG, Kim SY, Kim HR, Kim H, et al
    Radiation Induces Autophagy via Histone H4 Lysine 20 Trimethylation in Non-small Cell Lung Cancer Cells.
    Anticancer Res. 2020;40:2537-2548.
    PubMed     Abstract available


  115. SHIBATA MA, Shibata E, Morimoto J, Kondo Y, et al
    Urethane-induced Mammary Carcinogenesis Susceptibility in Transgenic Mice Expressing a Dominant-negative TGF-beta Type II Receptor.
    Anticancer Res. 2020;40:2687-2694.
    PubMed     Abstract available


  116. AOKI M, Ueda K, Umehara T, Kamimura GO, et al
    Targeted Therapy Followed by Cytotoxic Chemotherapy in Preoperative Patients With Locally Advanced Lung Adenocarcinoma.
    Anticancer Res. 2020;40:2911-2916.
    PubMed     Abstract available


    April 2020
  117. TONE M, Inomata M, Awano N, Kuse N, et al
    Salvage Chemotherapy Following Osimertinib in Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
    Anticancer Res. 2020;40:2239-2246.
    PubMed     Abstract available


  118. SVATON M, Zemanova M, Zemanova P, Kultan J, et al
    Impact of Concomitant Medication Administered at the Time of Initiation of Nivolumab Therapy on Outcome in Non-small Cell Lung Cancer.
    Anticancer Res. 2020;40:2209-2217.
    PubMed     Abstract available


  119. MOUNTZIOS G, Mavropoulou X, Koliou GA, Linardou H, et al
    Impact of Bevacizumab Versus Erlotinib on Tumor Metrics in Patients With Previously Untreated Advanced Non-small Cell Lung Cancer: A Study by the Hellenic Cooperative Oncology Group.
    Anticancer Res. 2020;40:2095-2106.
    PubMed     Abstract available


  120. KIM DH, Sp N, Kang DY, Jo ES, et al
    Effect of Methylsulfonylmethane on Proliferation and Apoptosis of A549 Lung Cancer Cells Through G2/M Cell-cycle Arrest and Intrinsic Cell Death Pathway.
    Anticancer Res. 2020;40:1905-1913.
    PubMed     Abstract available


  121. YAN L, Rust BM, Picklo MJ
    Plasma Metabolomic Changes in Mice With Time-restricted Feeding-attenuated Spontaneous Metastasis of Lewis Lung Carcinoma.
    Anticancer Res. 2020;40:1833-1841.
    PubMed     Abstract available


  122. YAMAMOTO T, Niibe Y, Matsumoto Y, Dekura Y, et al
    Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Esophageal Cancer: Results and Prognostic Factors.
    Anticancer Res. 2020;40:2065-2072.
    PubMed     Abstract available


  123. TU YN, Tong WL, Callahan BM, Chobrutskiy BI, et al
    B-cell Receptor Recombinations in Lung Adenocarcinoma Exome Files Correlate With a Higher Overall Survival Rate.
    Anticancer Res. 2020;40:2043-2051.
    PubMed     Abstract available


  124. ZHAO S, Guo X, Taniguchi M, Kondo K, et al
    Detection of Mediastinal Lymph Node Metastases Using Indocyanine Green (ICG) Fluorescence Imaging in an Orthotopic Implantation Model.
    Anticancer Res. 2020;40:1875-1882.
    PubMed     Abstract available


  125. SHUKUYA T, Oyanagi J, Serizawa M, Watanabe M, et al
    Hypoxia Inducible Factor-1alpha Inhibition in Von Hippel Lindau-mutant Malignant Pleural Mesothelioma Cells.
    Anticancer Res. 2020;40:1867-1874.
    PubMed     Abstract available


  126. LUU TT, Bach DH, Kim D, Hu R, et al
    Overexpression of AGR2 Is Associated With Drug Resistance in Mutant Non-small Cell Lung Cancers.
    Anticancer Res. 2020;40:1855-1866.
    PubMed     Abstract available


  127. HOFFMANN M, Reitz D, Taugner J, Roengvoraphoj O, et al
    Blood Parameters Demonstrating a Significant Survival Impact in Patients With Locally Advanced NSCLC Undergoing Definitive Chemoradiotherapy.
    Anticancer Res. 2020;40:2319-2322.
    PubMed     Abstract available


  128. SCHALLIER D, Lesfevre P, Everaert H
    Antitumor Activity of Cabozantinib in Metastatic Adult Ewing Sarcoma: A Case Report.
    Anticancer Res. 2020;40:2265-2269.
    PubMed     Abstract available


  129. SIMETIC L, Blazicevic K, Medugorac K, Golcic M, et al
    Relative Change in S100 as a Biomarker of Survival in Patients With Metastatic Melanoma Treated With Pembrolizumab.
    Anticancer Res. 2020;40:2157-2163.
    PubMed     Abstract available


    March 2020
  130. LIU Y, Huber RM, Kiefl R, Tufman A, et al
    Hedgehog Pathway Activation Might Mediate Pemetrexed Resistance in NSCLC Cells.
    Anticancer Res. 2020;40:1451-1458.
    PubMed     Abstract available


  131. DURAN-MORENO J, Kokkali S, Ramfidis V, Salomidou M, et al
    Primary Sarcoma of the Lung - Prognostic Value of Clinicopathological Characteristics of 26 Cases.
    Anticancer Res. 2020;40:1697-1703.
    PubMed     Abstract available


  132. ARSHI J, Sauer M, Yin F
    Rapid Sarcomatoid Transformation of Lung Squamous Cell Carcinoma After Neoadjuvant Therapy: A Case Report.
    Anticancer Res. 2020;40:1625-1629.
    PubMed     Abstract available


  133. IMAI H, Kaira K, Naruse I, Kasahara N, et al
    Prospective Feasibility Study of Amrubicin and Bevacizumab Therapy for Patients With Previously Treated Advanced NSCLC.
    Anticancer Res. 2020;40:1571-1578.
    PubMed     Abstract available


  134. SAKATA KI, Maeda K, Sakurai N, Liang S, et al
    ADAR2 Regulates Malignant Behaviour of Mesothelioma Cells Independent of RNA-editing Activity.
    Anticancer Res. 2020;40:1307-1314.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: